Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramide mustard, which has shown safety and signals of efficacy in a prior phase 1 study in recurrent glioblastoma. We performed a dual center single-arm Phase II stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Andrew J., Floyd, John, Fichtel, Lisa, Michalek, Joel, Kanakia, Kunal P., Huang, Shiliang, Reardon, David, Wen, Patrick Y., Lee, Eudocia Quant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841164/
https://www.ncbi.nlm.nih.gov/pubmed/33504881
http://dx.doi.org/10.1038/s41598-021-81841-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841164/
https://www.ncbi.nlm.nih.gov/pubmed/33504881
http://dx.doi.org/10.1038/s41598-021-81841-0

Ejemplares similares